Quarterly ResultMay 7, 2026, 07:22 AM
Xeris Biopharma Q1 Total Revenue $83.1M, +38%; Raises FY26 Guidance
AI Summary
Xeris Biopharma reported strong first-quarter 2026 financial results, with total revenue increasing 38% year-over-year to $83.1 million. This growth was primarily driven by a 43% rise in total product revenue, notably Recorlev net revenue which nearly doubled to $49.8 million. The company achieved a net income of $2.2 million, a significant improvement from a net loss in the prior year, and tightened its full-year 2026 total revenue guidance to $380 million to $390 million.
Key Highlights
- Total revenue for Q1 2026 increased 38% year-over-year to $83.1 million.
- Total product revenue rose 43% year-over-year to $82.5 million.
- Recorlev net revenue surged 95% year-over-year to $49.8 million.
- Net income for Q1 2026 was $2.2 million, compared to a $9.2 million net loss in Q1 2025.
- Adjusted EBITDA improved to $15.1 million from $4.4 million in the prior year.
- Full-year 2026 total revenue guidance tightened to $380 million to $390 million.
- Gross margin improved to 87% from 85% in the same period last year.
- Anticipates Phase 3 initiation of XP-8121 later in 2026.